Trending...
- New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
- New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
- Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 27, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) common stock between February 26, 2020 and April 19, 2022, inclusive (the "Class Period").
Investors suffering losses on their Natera investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, including Natera's Panorama test, alleging that positive results on tests are incorrect approximately 85 percent of the time, and that patients who receive a positive result are supposed to pursue follow-up testing, which "can cost thousands of dollars, come with a small risk of miscarriage and can't be performed until later in pregnancy."
On this news, Natera's stock price fell $5.35, or 5.7%, over two trading days to close at $88.04 per share on January 4, 2022, thereby injuring investors.
Then, on January 14, 2022, a nonprofit watchdog group filed a complaint with the SEC requesting an investigation into whether Natera had "repeatedly" claimed that its tests were "much more reliable than it appears they really are."
More on The PennZone
On this news, Natera's stock fell $6.29, or 9.3%, to close at $61.08 per share on January 18, 2022.
On March 9, 2022, Hindenburg Research published a report which alleged, among other things, that Natera's revenue growth has been "fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers."
On this news, Natera's stock price fell $17.95, or 32.8%, to close at $36.80 per share on March 9, 2022, thereby further injuring investors.
Then, on March 14, 2022, a Delaware District Court jury found that Natera had engaged in false advertising, including claims that its kidney transplant test, Prospera, was more accurate than its competing tests.
On this news, Natera's stock price fell $5.57 per share, or 15.5%, to close at $30.32 per share on March 15, 2022, thereby further injuring investors.
Then, on April 19, 2022, the United States Food and Drug Administration ("FDA") issued a safety communication "to educate patients an health care providers and to help reduce the inappropriate use" of non-invasive prenatal tests ("NIPT"), cautioning that NIPTs reliability and accuracy "may not be supported with sound scientific evidence," revealing that there had been "cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy."
On this news, Natera's stock fell $1.53, or 3.9%, to close at $38.63 per share on April 19, 2022, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
If you purchased or otherwise acquired Natera common stock during the Class Period, you may move the Court no later than June 27, 2022 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Investors suffering losses on their Natera investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, including Natera's Panorama test, alleging that positive results on tests are incorrect approximately 85 percent of the time, and that patients who receive a positive result are supposed to pursue follow-up testing, which "can cost thousands of dollars, come with a small risk of miscarriage and can't be performed until later in pregnancy."
On this news, Natera's stock price fell $5.35, or 5.7%, over two trading days to close at $88.04 per share on January 4, 2022, thereby injuring investors.
Then, on January 14, 2022, a nonprofit watchdog group filed a complaint with the SEC requesting an investigation into whether Natera had "repeatedly" claimed that its tests were "much more reliable than it appears they really are."
More on The PennZone
- Tek84 Unveils New Brand Identity Built to Magnify What Security Officers Can Do
- CoreVar Announces Cooking with AI, an Eight-Topic Live Webinar Series
- Mr Hospital Bed Cites Hill Rom Hospital Bed Models Best Value Home Care Hospital Beds 2026
- Dr. Lynn Peterson Releases Food: The Final Frontier on Food and Chronic Disease
- Tucker Chiropractic Center Highlights a Root-Cause Approach to Pain Relief & Wellness
On this news, Natera's stock fell $6.29, or 9.3%, to close at $61.08 per share on January 18, 2022.
On March 9, 2022, Hindenburg Research published a report which alleged, among other things, that Natera's revenue growth has been "fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers."
On this news, Natera's stock price fell $17.95, or 32.8%, to close at $36.80 per share on March 9, 2022, thereby further injuring investors.
Then, on March 14, 2022, a Delaware District Court jury found that Natera had engaged in false advertising, including claims that its kidney transplant test, Prospera, was more accurate than its competing tests.
On this news, Natera's stock price fell $5.57 per share, or 15.5%, to close at $30.32 per share on March 15, 2022, thereby further injuring investors.
Then, on April 19, 2022, the United States Food and Drug Administration ("FDA") issued a safety communication "to educate patients an health care providers and to help reduce the inappropriate use" of non-invasive prenatal tests ("NIPT"), cautioning that NIPTs reliability and accuracy "may not be supported with sound scientific evidence," revealing that there had been "cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy."
On this news, Natera's stock fell $1.53, or 3.9%, to close at $38.63 per share on April 19, 2022, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
- WOWX labs Closes US$10 Million Founder-Led Growth Financing as WOWX.market Enters Scale Phase
- BESTBUYSTORE opens its dropshipping model to independent merchants
- America's Hometown Thanksgiving Parade in Plymouth, MA, on Saturday, November 21, 2026
- Navigating a Changing Market: How AIX Group Is Responding to a Challenging Year
- 450 Million Revenue Run Rate, Global Telecom Reach and a New Digital Growth Opportunity Take Center Stage: IQSTEL, Inc. (N A S D A Q: IQST)
If you purchased or otherwise acquired Natera common stock during the Class Period, you may move the Court no later than June 27, 2022 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
0 Comments
Latest on The PennZone
- ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection
- National Literacy and Workforce Readiness Crisis Sparks New Program Launching in Birmingham
- New England Consulting Partners Celebrates 25 Years of Turnaround Management Solutions
- RAS AP Consulting Releases Educational Resource to Help Organizations Prepare for IRS FIRE-to-IRIS Transition
- York County Is an EPA Radon Zone 1. Here Is What Homeowners Should Know Before Testing
- What Mold Remediation Costs in Gettysburg, PA: 2026 Price Ranges by Job Type
- Roots, Rhythm & Joy Invites Neighbors to Find Community Through Music
- New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
- Stand Strong Fencing of Hatfield Turns Every October Project Into a Cancer Donation
- New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
- Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner
- Heritage at Manalapan Announces Limited-Time Mortgage Rate Buydown on Select Quick Move-In Homes
- Good Organics Now at Pop Up Grocer NYC With October 30 Sampling Event
- KeysCaribbean Announces Temporarily Reduced Rates At Village at Hawks Cay Villas
- Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
- Electives Launches "Electives for Everyone," Making Live Expert-Led Learning Available to Every Employee
- Tax Tops the List as Wealthy Brits Plan Their Exit, La Vida Survey Finds
- "The Tree of Cinema" Installation Brought Film History and Its Audiences Together at TIFF 2026
- Detroit Lawyer Steals $600,000 Settlement Meant to Protect Child
- The Great Junk Hunt Makes Its Highly Anticipated Stop in Philadelphia (Oaks)!